Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance

Charles, Zoe; Pugh, Edwin; Barnett, Donald M.

doi:10.1136/hrt.2007.138263

Cited by 14 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The UK National Institute for Health and Clinical Excellence (NICE) guidance recently reviewed the results of several randomized controlled clinical trials with ezetimibe in patients with primary HC, with and without prior CVD 7. Average baseline LDL-C concentrations ranged from 3.4 to 6.5 mmol/L.…”

Section: Ezetimibe In Primary Hcmentioning

confidence: 99%

See 1 more Smart Citation

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Hamilton-Craig¹

2010

VHRM

View full text Add to dashboard Cite

High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin–ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

show abstract

Section: Ezetimibe In Primary Hcmentioning

confidence: 99%

“…To represent the population of people with HC that is not appropriately controlled with statin therapy, six 12-week, fixed-dose randomized controlled trials (RCTs, n = 3,610) were identified that compared ezetimibe plus statin therapy with statin therapy alone 7. The NICE Assessment Group carried out a meta-analysis on the RCTs.…”

Section: Ezetimibe In Primary Hcmentioning

confidence: 99%

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Hamilton-Craig¹

2010

VHRM

View full text Add to dashboard Cite

show abstract

“…They are most effective in reducing LDL-C 5 . Ezetimibe monotherapy is recommended as an option for treatment for adults who are intolerant to statin therapy, co-administered with initial statin therapy, is recommended as an option for treatment of adults who have been initiated on statin therapy when serum TC or LDL-C concentration is not appropriately controlled either after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy 6 . This study was carried out in the outpatient department of Rizgary Teaching Hospital in Erbil city, for a period of 6 months.…”

Section: Introductionmentioning

confidence: 99%

Effect of atorvastatin, with or without ezetimibe, on serum lipid profile and ALT in hyperlipidemic patients

Husain

Hamad

2011

ZJMS

View full text Add to dashboard Cite

Background and objectives:Hyperlipidaemia is raised serum levels of one or more of total cholesterol, low-density lipoprotein and triglycerides. Many drugs have been used for the treatment of this disorder. This work compares the effects of atorvastatin with or without ezetimibe on lipid profile, atherogenic index and serum alanine aminotransferase. Methods: This study covers 90 subjects, 60 untreated hyperlipidemic patients, and 30 healthy subjects. Patients were divided into 2 groups, the first group included 30 patients treated with atorvastatin 20 mg/day alone, the second group included 30 patients treated with a combination of 2 drugs (atorvastatin 10 mg plus ezetimibe 10 mg) taken daily at night. Serum lipid profile, atherogenic index and serum alanine amniotransferase were measured after 12 hours fasting for the patients in 3 intervals: before, and after 8 weeks and 16 weeks of treatment. Results: After therapy for both groups of patients, as compared to the levels before treatment, has shown that serum total cholesterol, triglycerides, low density lipoprotein cholesterol and very low density lipoprotein cholesterol were significantly reduced while high density lipoprotein cholesterol was significantly increased. Serum alanine aminotransferase increased by both groups of treatment with no significant difference between the two modes of treatment which has the same findings in comparison to the control group. Conclusion: Combination of atorvastatin 10 mg and ezetimibe 10 mg daily, is more effective than atorvastatin 20 mg taken alone. Key words: hyperlipidaemia ,atherogenic index , atorvastatin ,ezetimibe, alanine aminotransferase Abstract

show abstract

“…The recently issued guidance from the National Institute for Health and Clinical Excellence (NICE)1 on the cholesterol absorption inhibitor ezetimibe is welcome and summarised in this issue of Heart 2. NICE recommends its use in combination with a statin when more intensive low-density lipoprotein (LDL) lowering is indicated, and as monotherapy in the small proportion of patients who are intolerant of statin or in whom a statin is contraindicated.…”

mentioning

confidence: 99%

Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia

Armitage

2008

Heart

View full text Add to dashboard Cite

Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance

Cited by 14 publications

References 0 publications

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Effect of atorvastatin, with or without ezetimibe, on serum lipid profile and ALT in hyperlipidemic patients

Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia

Contact Info

Product

Resources

About